Last update 01 Nov 2024

Sph Biocad Hk Ltd.

Private Company|
2019|
Hong Kong SAR, China

Overview

Tags

Urogenital Diseases
Skin and Musculoskeletal Diseases
Neoplasms
Monoclonal antibody
Biosimilar

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Endocrinology and Metabolic Disease1
Infectious Diseases1
Immune System Diseases1
Nervous System Diseases1
Top 5 Drug TypeCount
Monoclonal antibody3
Biosimilar1
Top 5 TargetCount
IL-17A(Interleukin 17A)1
PD-1(Programmed cell death protein 1)1
VEGF-A(Vascular endothelial growth factor A)1

Related

3
Drugs associated with Sph Biocad Hk Ltd.
Prolgolimab
Target
PD-1
Mechanism
PD-1 inhibitors
Active Org.
Biocad CJSCBiocad CJSC [+3]
Originator Org.
Biocad Medical, Inc.
Active Indication
Melanoma [+4]
Inactive Indication
Advanced Lung Non-Squamous Non-Small Cell Carcinoma [+7]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
RU
First Approval Date01 Apr 2020
Netakimab
Target
IL-17A
Mechanism
IL-17A inhibitors
Active Org.
Biocad CJSCBiocad CJSC [+1]
Originator Org.
Biocad Medical, Inc.
Active Indication
Arthritis, Psoriatic [+2]
Inactive Indication
Primary Biliary Cholangitis
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
RU
First Approval Date04 Apr 2019
Bevacizumab biosimilar(Biocad Medical, Inc.)
Target
VEGF-A
Mechanism
VEGF-A inhibitors [+1]
Active Org.
Biocad Medical, Inc. [+4]
Originator Org.
Biocad Medical, Inc.
Active Indication
Colorectal Cancer [+5]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
RU
First Approval Date25 Nov 2015
5
Clinical Trials associated with Sph Biocad Hk Ltd.
CTR20241245 / RecruitingPhase 3
一项在中国成年中重度斑块状银屑病患者中评估皮下注射Netakimab的有效性、安全性及药代动力学特征和免疫原性的随机、双盲、安慰剂对照、多中心临床研究
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical study to evaluate the efficacy, safety, pharmacokinetic characteristics and immunogenicity of subcutaneous Netakimab in Chinese adult patients with moderate to severe plaque psoriasis
CTR20222555 / Active, not recruitingPhase 3
一项在中国成年活动性强直性脊柱炎患者中评估皮下注射Netakimab的有效性、安全性及药代动力学特征和免疫原性的随机、双盲、安慰剂对照、多中心研究
[Translation] A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetic characteristics and immunogenicity of subcutaneous Netakimab in Chinese adult patients with active ankylosing spondylitis
CTR20222646 / CompletedPhase 1
一项在中国健康受试者中评价Netakimab注射液单次皮下给药的药代动力学特征、安全性、耐受性和免疫原性的 I期、开放性临床研究
[Translation] A Phase I, open-label clinical study to evaluate the pharmacokinetic characteristics, safety, tolerability and immunogenicity of a single subcutaneous dose of Netakimab injection in healthy Chinese subjects
100 Clinical Results associated with Sph Biocad Hk Ltd.
Login to view more data
0 Patents (Medical) associated with Sph Biocad Hk Ltd.
Login to view more data
100 Deals associated with Sph Biocad Hk Ltd.
Login to view more data
100 Translational Medicine associated with Sph Biocad Hk Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Application
1
2
Phase 3 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Prolgolimab
 ( PD-1 )		-
Phase 3
Netakimab
 ( IL-17A )		Ankylosing Spondylitis
More
Phase 3
Bevacizumab biosimilar(Biocad Medical, Inc.)
 ( VEGF-A )		Solid tumor
More
IND Application
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free